Status:
COMPLETED
A Non-interventional Study of Remazolam Methyl Benzene Sulfonic Acid for Injection in Real-world Clinical Practice
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Conditions:
Gastroscopic and Colonoscopic Sedation
Eligibility:
All Genders
Brief Summary
This is a non-interventional study of remazolam toluenesulfonate (rebenin ®) for injection in Chinese patients. A total of 2000 patients were enrolled in this study based on the preliminary safety ass...
Eligibility Criteria
Inclusion
- Use rebenin ® for painless gastroscopic sedation and painless colonoscopic sedation
- Patients need to sign informed consent
Exclusion
- Patients who are participating in or planning to participate in any interventional clinical trial
- The investigator considers that there are any other reasons for the patient's ineligibility for the study
Key Trial Info
Start Date :
January 30 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 8 2023
Estimated Enrollment :
2022 Patients enrolled
Trial Details
Trial ID
NCT05254366
Start Date
January 30 2022
End Date
February 8 2023
Last Update
January 5 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430021